循环miR-101-3p在妊娠期糖尿病诊断中的作用研究

摘要
图/表
参考文献
相关文章 (7)

全文: PDF (4209 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的：探讨妊娠期糖尿病（GDM）女性循环miRNAs的差异表达,确定GDM相关的潜在分子标志物。方法：采集自2020年1月―2022年6月期间西北妇女儿童医院的53名GDM孕妇和30名年龄和孕周相匹配的正常孕妇的血浆样本。采用miRNA高通量测序筛选GDM相关的循环miRNA,实时定量PCR（RT-qPCR）验证。使用受试者工作特征（ROC）曲线评估循环miR-101-3p预测GDM的价值。采用酶联免疫吸附法测定血清hs-CRP、TNF-α水平。结果：与健康对照组相比,GDM组孕妇具有较高的甘油三酯、hs-CRP、TNF-α水平和较低的HDL-C水平。在检测的2549个血浆miRNA中,267个miRNA的表达在两组之间显示出2倍或更大的差异。PCR分析显示,与健康受试者相比,GDM孕妇的血浆miR-101-3p显著下调。KEGG途径富集发现,miR-101-3p可能参与葡萄糖、炎症调节和脂质的代谢。ROC曲线分析显示,miR-101-3p区分健康对照组和GDM组的敏感性为0.852,特异性为0.737,AUC值为0.845。相关性分析显示,血浆miR-101-3p的表达与血糖水平、hs-CRP、TNF-α呈显著负相关（r=-0.649、-0.602、-0.735,均P<0.001）。结论：miR-101-3p可能参与GDM患者的胰岛素抵抗和炎症因子调节。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	贾梦
	王剑鹰
	吉婷
	贾菲
	刘晶

关键词 ：妊娠期糖尿病, 胰岛素抵抗, miRNAs, 炎症因子

Abstract：Objective To explore the differential expression of circulating miRNAs between healthy women and women with gestational diabetes mellitus (GDM), and to identify potential molecular markers related to GDM. Methods Plasma samples were taken from 53 pregnant women with GDM and 30 normal pregnant women with matched age and gestational weeks in Northwest Women's and Children's Hospital from January 2020 to June 2022. The miRNA high-throughput sequencing was used to screen circulating miRNAs related to GDM. Real-time quantitative PCR (RT-qPCR) was used to verify the differentially expressed candidate miRNAs identified from the mirna analysis experiment. Evaluating the expression level of circulating miR-101-3p by using receiver operating characteristic (ROC) curve to predict the value of GDM. Serum hs-CRP and TNF-α levels were measured by enzyme-linked immunosorbent assay. Results Compared with the healthy control group, pregnant women in GDM group had higher levels of triglyceride, hs-CRP, TNF-α and lower levels of HDL-C. Among the 2549 plasma mirnas detected, 267 mirnas showed 2 times or more difference in expression between the two groups. Enrichment of KEGG pathway revealed that miR-101-3p may be involved in glucose, inflammation regulation and lipid metabolism. PCR analysis showed that the plasma miR-101-3p of GDM pregnant women was significantly down-regulated compared with healthy subjects. ROC analysis showed that the sensitivity, specificity and AUC of miR-101-3p in distinguishing healthy control group from GDM group were 0.852, 0.737 and 0.845, respectively. Correlation analysis showed that the expression of plasma miR-101-3p was negatively correlated with blood glucose level, hs-CRP and TNF-α (r=-0.649, -0.602 and -0.735, all P<0.001). Conclusions MiR-101-3p may be involved in insulin resistance and the regulation of inflammatory factors in GDM patients.

Key words： gestational diabetes insulin resistance miRNAs inflammatory factor

收稿日期: 2022-11-30

中图分类号:

R714.256

基金资助:陕西省卫生健康科研基金（2018D036）

通讯作者: 刘晶,E-mail：Xiaomiguo2018@163.com

引用本文:

贾梦, 王剑鹰, 吉婷, 贾菲, 刘晶. 循环miR-101-3p在妊娠期糖尿病诊断中的作用研究[J]. 湖南师范大学学报(医学版), 2023, 20(3): 38-42. JIA Meng, WANG Jianying, JI Ting, JIA Fei, LIU Jing. Study on the role of circulating miR-101-3p in the diagnosis of gestational diabetes mellitus. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 38-42.

链接本文:

http://yxb.hunnu.edu.cn/CN/ 或 http://yxb.hunnu.edu.cn/CN/Y2023/V20/I3/38

[1] 凌思思, 徐琦, 郑小冬, 等. 妊娠早期炎症因子与妊娠期糖尿病发生的相关性初步探讨[J]. 中华妇产科杂志, 2020, 55(5): 333-337.
[2] Jowell A R, Sarma A A, Gulati M, et al.Interventions to mitigate risk of cardiovascular disease after adverse pregnancy outcomes: a review[J]. JAMA Cardiol, 2022, 7(3): 346-355.
[3] 马玉着, 陈素玉, 刘昱婕. 妊娠期糖尿病患者血清miR-15a表达水平及其与母婴不良结局的关系[J]. 安徽医科大学学报, 2022, 57(4): 650-654.
[4] Masete M, Dias S, Malaza N, et al.A big role for microRNAs in gestational diabetes mellitus[J]. Front Endocrinol, 2022, 13: 892587.
[5] Tagoma A, Alnek K, Kirss A, et al.MicroRNA profiling of second trimester maternal plasma shows upregulation of miR-195-5p in patients with gestational diabetes[J]. Gene, 2018, 672: 137-142.
[6] Landrier J F, Derghal A, Mounien L.MicroRNAs in obesity and related metabolic disorders[J]. Cells, 2019, 8(8): 859.
[7] Hocaoglu M, Demirer S, Senturk H, et al.Differential expression of candidate circulating microRNAs in maternal blood leukocytes of the patients with preeclampsia and gestational diabetes mellitus[J]. Pregnancy Hypertens, 2019, 17: 5-11.
[8] Gillet V, Ouellet A, Stepanov Y, et al.miRNA profiles in extracellular vesicles from serum early in pregnancies complicated by gestational diabetes mellitus[J]. J Clin Endocrinol Metab, 2019, 104(11): 5157-5169.
[9] Zhang L, Li K, Tian S, et al.Down-regulation of microRNA-30 d-5p is associated with gestational diabetes mellitus by targeting RAB8A[J]. J Diabetes Complications, 2021, 35(8): 107959.
[10] Meroni M, Longo M, Erconi V, et al.mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance[J]. Nutrients, 2019, 11(11): 2597.
[11] Santos A S, Cunha Neto E, Fukui R T, et al.Increased expression of circulating microRNA 101-3p in type 1 diabetes patients: new insights into miRNA-regulated pathophysiological pathways for type 1 diabetes[J]. Front Immunol, 2019, 10: 1637.
[12] Song L, Feng S, Yu H, et al.Dexmedetomidine Protects Against Kidney Fibrosis in Diabetic Mice by Targeting miR-101-3p-Mediated EndMT[J]. Dose Response, 2022, 20(1): 15593258221083486.
[13] Zhao X, Su F, Kong F, et al.miR-101-3p contributes to the progression of preeclampsia by suppressing WDR5-mediated proliferation and invasion of trophoblast[J]. J Obstet Gynaecol Res, 2023, 49(1): 141-153.
[14] Liu W, Huang Z, Tang S, et al.Changes of serum sex hormone-binding globulin, homocysteine, and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus[J]. Gynecol Obstet Invest, 2021, 86(1): 193-199.
[15] Hu J, Gillies C L, Lin S, et al.Association of maternal lipid profile and gestational diabetes mellitus: A systematic review and meta-analysis of 292 studies and 97, 880 women[J]. EClinicalMedicine, 2021, 34: 100830.
[16] Zhao X, Li S, Wang Z, et al.miR-101-3p negatively regulates inflammation in systemic lupus erythematosus via MAPK1 targeting and inhibition of the NF-κB pathway[J]. Mol Med Rep, 2021, 23(5): 359.